Pfizer Inc

Pfizer’s latest filings reveal a strategic mix of executive share‑ownership, a bold Lucy Liu oncology ad campaign, and a plan to navigate FDA warnings while tackling patent cliffs with new mRNA‑driven vaccines and potential biotech M&A.

Pfizer’s virtual 2026 shareholder meeting and new board scientist boost transparency and clinical focus, while promising therapeutics like PF‑001 and PF‑VAX edge closer to approval.

Pfizer’s share dip stems from weak demand for Paxlovid, Prevnar and Vyndamax, but new cash inflows from ViiV divestiture and a European court win may cushion the blow.

Pfizer’s stock dips as sales forecasts fall, but strategic divestitures and a promising Lyme vaccine pipeline may offset revenue erosion and boost long‑term growth.

Pfizer’s San Diego R&D consolidation and cost‑cutting plan aim to offset patent cliffs, boost margins, and accelerate GLP‑1 and antibody‑drug conjugate launches amid rising institutional interest.

Pfizer’s low valuation, strong earnings, GLP‑1 pipeline, and tariff‑exemption strategy make it a value‑driven pick amid evolving drug‑tariff rules.

Pfizer’s €1.9 billion court ruling, trial pause, and ViiV divestiture illustrate how the pharma giant balances legal risks, enrollment challenges, and strategic growth to protect cash flow, patient access, and high‑margin portfolio value.

Pfizer’s latest earnings beat forecasts, driven by strong immunology and oncology sales, while ETF inflows boost confidence. Discover how its haemophilia pipeline and fusion‑protein platform could reshape revenue and keep investors wary of exec‑stoc…

Pfizer’s latest corporate moves: phantom‑stock conversion aligns executive ownership, Fc‑fusion biologics lead in trials, and legal tech cuts litigation costs.

Pfizer’s Q4 earnings beat, strong oncology pipeline and strategic M&A plans position it to weather patent cliffs and capture growth in the competitive drug market.